Newbury Pharmaceuticals AB (OSTO:NEWBRY) Moat Score: 0/10 (As of Aug. 28, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:NEWBRY Newbury Pharmaceuticals AB OSTO:NEWBRY
41 GF Score
Price kr2.48
GF Value kr3.20
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Newbury Pharmaceuticals AB Moat Score?

Newbury Pharmaceuticals AB has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Newbury Pharmaceuticals AB has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Newbury Pharmaceuticals AB might have No Moat - No discernible moat.

Newbury Pharmaceuticals AB  (OSTO:NEWBRY) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Newbury Pharmaceuticals AB Moat Score Related Terms

OSTO:NEWBRY
41GF Score
Newbury Pharmaceuticals AB OSTO:NEWBRY
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Newbury Pharmaceuticals AB (OSTO:NEWBRY) Overvalued in 2026?

Based on GuruFocus' analysis, Newbury Pharmaceuticals AB stock appears to be undervalued. The current stock price of kr2.48 is trading 22.5% below its estimated GF Value™ of kr3.20. GuruFocus considers Newbury Pharmaceuticals AB to be Modestly Undervalued.

Key valuation signals for OSTO:NEWBRY:

  • Moat Score: 0
  • GF Value™: kr3.20 vs. price of kr2.48 (22.5% below fair value)
  • GF Score™: 41/100 with 6 warning signs

No single metric tells the full story. See the OSTO:NEWBRY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Newbury Pharmaceuticals AB Business Description

Other Exchanges P52:Germany
Address Scheeletorget 1, Medicon Village, Lund, SWE, 223 81
Newbury Pharmaceuticals AB is a hybrid pharmaceutical company for specialty prescription drugs, innovation and brands with focus on the Scandinavian markets.
41GF Score

Get the complete analysis for OSTO:NEWBRY

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr2.48
Price
kr3.20
GF Value